ZVRA · Zevra Therapeutics, Inc. · Executive Compensation
$10.33
-0.03 (-0.29%)
At close · Oct 22
Return incl. dividend (before tax)
Market Cap
$614.03M
Shares
59.38M
Volume · Oct 22
537.3K
Avg daily vol (3M)
1.05M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| LaDuane Clifton | MBA, CPA Former Chief Financial Officer and Treasurer | $3,821,924 |
| Neil F. McFarlane | President, Chief Executive Officer and Director | $3,782,042 |
| Rahsaan W. Thompson | Chief Legal Officer, Secretary and Compliance Officer | $1,571,374 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Neil F. McFarlane | President, Chief Executive Officer and Director | $5,355,059 |
| LaDuane Clifton | MBA, CPA Former Chief Financial Officer and Treasurer | $1,450,273 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Richard W. Pascoe | Former Chief Executive Officer and Director | $4,122,558 |
| Richard Pascoe | CEO | $4,122,558 |
| Travis Mickle | Former President, Chief Executive Officer and Director | $3,593,438 |
| Neil F. McFarlane | President, Chief Executive Officer and Director | $3,445,231 |
| LaDuane Clifton | MBA, CPA Chief Financial Officer, Secretary and Treasurer | $2,263,257 |
| Joshua M. Schafer | Chief Commercial Officer and Executive Vice President, Business Development | $1,814,465 |
| Christal Mickle | CEO | $1,669,956 |
| Christal M.M. Mickle | M.A. Former Interim Chief Executive Officer | $1,669,956 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Travis Mickle | Former President, Chief Executive Officer and Director | $2,400,356 |
| Richard Pascoe | CEO | $1,360,976 |
| Richard W. Pascoe | Former Chief Executive Officer and Director | $1,360,976 |
| LaDuane Clifton | MBA, CPA Chief Financial Officer, Secretary and Treasurer | $1,038,007 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Travis Mickle | President, chief executive officer and director | $2,657,059 |
| Sven Guenther | Executive vice president, research and development | $1,082,153 |
| LaDuane Clifton | Chief financial officer, secretary and treasurer | $1,056,212 |
| Richard Pascoe | Chairman | $712,482 |
| Richard W. Pascoe | Executive chairman | $712,482 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Travis Mickle | President, chief executive officer and director | $967,979 |
| Sven Guenther | Executive vice president, research and development | $563,331 |
| LaDuane Clifton | Chief financial officer, secretary and treasurer | $541,114 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Travis Mickle | President, chief executive officer and chairman of the board | $1,360,174 |
| Sven Guenther | Executive vice president, research and development | $687,731 |
| LaDuane Clifton | Chief financial officer, secretary and treasurer | $664,487 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Travis Mickle | President, chief executive officer and chairman of the board | $1,423,379 |
| Sven Guenther | Executive vice president, research and development | $693,606 |
| LaDuane Clifton | Chief financial officer, secretary and treasurer | $647,324 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Justin Renz | principal financial officer | Appointed | 2026-03-09 |
| Justin Renz | Chief Financial Officer and Treasurer | Appointed | 2026-03-09 |
| Timothy Sangiovanni | interim principal financial officer | Appointed | 2025-12-17 |
| Alicia Secor | director | Appointed | 2025-12-02 |
| Wendy Dixon | Director | Resigned | 2025-12-02 |
| R. LaDuane Clifton | Chief Financial Officer and Treasurer and principal financial officer | Resigned | 2025-11-20 |
| Alvin Shih, M.D. | director | Appointed | 2024-01-23 |
| Joseph B. Saluri | member of the Board of the Company | Resigned | 2023-10-10 |
| Neil F. McFarlane | member of the Board | Appointed | 2023-10-10 |
| Neil F. McFarlane | President and Chief Executive Officer | Appointed | 2023-10-10 |
| Matthew R. Plooster | member of the Board of the Company | Resigned | 2023-08-07 |
| Thomas Anderson | director | Appointed | 2023-08-07 |
| John B. Bode | Board of Directors | Appointed | 2023-05-15 |
| Corey Watton | Board of Directors | Appointed | 2023-05-15 |
| Wendy Dixon | Board of Directors | Appointed | 2023-05-15 |
| Douglas E. Calder | Board of Directors | Appointed | 2023-05-15 |
| Richard W. Pascoe | Chief Executive Officer | Resigned | 2023-05-15 |
| Tamara A. Favorito | Chair of the Board of Directors | Appointed | 2023-05-15 |
| Christal M.M. Mickle | interim President and Chief Executive Officer | Appointed | 2023-05-15 |
| Richard W. Pascoe | Chief Executive Officer | Resigned | 2023-05-08 |
| Travis Mickle | director | Resigned | 2023-03-30 |
| Wendy L. Dixon, Ph.D. | director | Appointed | 2023-03-30 |
| Travis C. Mickle | Chief Executive Officer | Resigned | 2023-01-09 |
| Richard W. Pascoe | Executive Chairman | Resigned | 2023-01-09 |
| Richard W. Pascoe | Chief Executive Officer | Appointed | 2023-01-09 |
Leadership
- Christal M.M. Mickle CEO
- Neil F. McFarlane CEO, Board Member
- Richard W. Pascoe CEO
- Matthew R. Plooster Chairman
- Richard Pascoe Chairman
- Tamara A. Favorito Chairman
- Timothy Sangiovanni CFO
- Alicia Secor Board Member
- Alvin Shih, M.D. Board Member
- Christopher A. Posner Board Member
- Corey Watton Board Member
- Douglas E. Calder Board Member
- John B. Bode Board Member
- Tamara A. Seymour Board Member
- Thomas Anderson Board Member
- Wendy Dixon Board Member
- Wendy L. Dixon, Ph.D. Board Member
Key facts
CIK
1434647
CUSIP
488445206
13F (30d)
22 filings
22 filers
Visit website
Investor relations